The Effect of Magnesium Oxide on Plasma Phosphate in Hemodialysis Patients
NCT ID: NCT01854437
Last Updated: 2013-05-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
42 participants
OBSERVATIONAL
2012-06-30
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ionized Magnesium Balance During Hemodialysis Session
NCT05337436
Potassium Flux in Hemodialysis Patients
NCT04287010
Defining The Role Of Dialysate Magnesium In Arrhythmogenicity On Dialysis
NCT00242164
Intracellular Phosphate Concentration Evolution During Hemodialysis by MR Spectroscopy
NCT03119818
Outcomes of a Higher vs. Lower Hemodialysate Magnesium Concentration (Dial-Mag Canada)
NCT04079582
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mg Oxide
Mg Oxide (Mg®, 21st Century®) 250 mg orally for 4 weeks
Mg Oxide
250 mg orally for 4 weeks
placebo
placebo 1 tab TDS
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mg Oxide
250 mg orally for 4 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shiraz University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Maryam Pakfetrat
associated professor of shiraz Shiraz University of Medical Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shiraz University Hemodialysis Center
Shiraz, Fars, Iran
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1391
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.